Gowling WLG advises Aegerion Pharmaceuticals on QLT merger to form Novelion Therapeutics

29 November 2016

On November 29, 2016, Aegerion Pharmaceuticals, Inc. completed its merger with QLT Inc. in which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the merger, QLT changed its name to Novelion Therapeutics Inc. Novelion is listed on NASDAQ and the Toronto Stock Exchange.

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases.

Gowling WLG acted as Canadian counsel to Aegerion with a team led by Henry Harris, which included Filomena Frisina, Paul Carenza, Ian Macdonald and Mariam Al-Shikarchy.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.